Survival in Stage IV Colorectal Cancer with Hepatic Metastasis and Peritoneal Carcinomatosis

Prognosis and Survival

The 5-year survival rate for patients with stage IV colorectal cancer and resectable hepatic metastases who achieve complete R0 resection is 20-45%, according to the American Society of Clinical Oncology 1

Complete resectability (R0) is the most important prognostic factor, as stated by the National Comprehensive Cancer Network 1, 2
Response to neoadjuvant chemotherapy significantly improves prognosis, as recommended by the European Society for Medical Oncology 1, 3
Mutational status, with RAS/BRAF wild-type tumors having a better prognosis, is noted by the American Joint Committee on Cancer 1
Metachronous metastases have a better prognosis than synchronous metastases, according to the Society of Surgical Oncology 1

For resectable hepatic metastases, administer perioperative chemotherapy with FOLFOX or FOLFIRI ± bevacizumab for 3 months preoperatively, followed by complete surgical resection of the primary tumor and metastases, and complete 3 additional months postoperatively (total 6 months), as recommended by the American Society of Clinical Oncology 1, 3

For a single metastasis <2 cm, proceed directly to surgery followed by 6 months of FOLFOX postoperatively, as suggested by the European Society for Medical Oncology 4, 3
For multiple metastases or >2 cm, administer 3 months of FOLFOX/FOLFIRI ± bevacizumab preoperatively, according to the National Comprehensive Cancer Network 1, 3
Reevaluate every 2 months during chemotherapy to determine conversion to resectability, as recommended by the Journal of the National Comprehensive Cancer Network 5, 2

For peritoneal carcinomatosis or irresectable hepatic metastases, systemic palliative chemotherapy with FOLFOX or FOLFIRI ± bevacizumab is the standard treatment, with a median survival of 15-21 months, as stated by the American Society of Clinical Oncology 5, 1

First-line: FOLFOX (oxaliplatin + leucovorin + fluorouracil) ± bevacizumab or FOLFIRI (irinotecan + leucovorin + fluorouracil) ± bevacizumab, as recommended by the National Comprehensive Cancer Network 5, 1
For KRAS/NRAS wild-type tumors, consider adding panitumumab or cetuximab, according to the European Society for Medical Oncology 5

Do not resect the asymptomatic primary tumor in the presence of irresectable metastatic disease, as stated by the American Society of Clinical Oncology 2, 3
Resect the primary tumor only if there is significant bleeding requiring transfusions, imminent obstruction (consider colonic stent as an alternative), or perforation, according to the National Comprehensive Cancer Network 2, 3

Avoid administering FOLFOX perioperatively to patients who failed within 12 months of prior adjuvant oxaliplatin; use FOLFIRI instead, as recommended by the European Society for Medical Oncology 4, 3
Do not allow complete radiological response before surgery, as lesions may become undetectable intraoperatively; reevaluate frequently, according to the American Society of Clinical Oncology 4, 3
Progression during neoadjuvant chemotherapy indicates aggressive tumor biology and poor prognosis even with resection, as noted by the National Comprehensive Cancer Network 4, 3
Bevacizumab requires an interval of 6-8 weeks before and after elective surgery due to the risk of complications in wound healing, as stated by the Journal of the National Comprehensive Cancer Network 5

Resection R0 + perioperative chemotherapy: 5-year survival rate 20-45%, according to the American Society of Clinical Oncology 1